Larimar Therapeutics, Inc. (LRMR)
About Larimar Therapeutics, Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2019
- $0
- Net income
- -$165.7M
- Total assets
- $145.8M
- Market cap
- $329.3M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $172.5M
- Operating income
- -$172.5M
- Income tax
- $0
- Net income
- -$165.7M
Balance sheet
- Total assets
- $145.8M
- Current assets
- $142.0M
- Total liabilities
- $67.8M
- Current liabilities
- $64.8M
- Shareholders’ equity
- $78.1M
Cash flow
- Operating cash flow
- -$113.2M
- Investing cash flow
- $100.3M
- Financing cash flow
- $65.1M
- Net cash flow
- $52.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $329.3M
- Shares outstanding
- 82.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 29, 2020
Larimar Therapeutics, Inc. (LRMR) Stock Price
- Reported a net loss of $165.7M in FY2019.
- Trading 33% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Larimar Therapeutics, Inc..
Write a review
News about Larimar Therapeutics, Inc.
News & sentiment via Polygon.io
Larimar Therapeutics, Inc.: frequently asked questions
Is Larimar Therapeutics, Inc. an American company?
Larimar Therapeutics, Inc. is a US-based company headquartered in Bala Cynwyd, Pennsylvania, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Larimar Therapeutics, Inc. headquartered?
Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania, United States.
Is Larimar Therapeutics, Inc. publicly traded?
Yes — Larimar Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol LRMR on the NASDAQ.
What does Larimar Therapeutics, Inc. do?
Larimar Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
